Objective-To investigate the role of recombinant human interleukin-11 (rhIL-11) on in vivo mobilization of CD34 ϩ / vascular endothelial growth factor receptor (VEGFR) 2 ϩ mononuclear cells and collateral vessel remodeling in a mouse model of hindlimb ischemia. Methods and Results-We observed that treatment of Sv129 mice with continuous infusion of 200-g/kg rhIL-11 per day led to in vivo mobilization of CD34 ϩ /VEGFR2 ϩ cells that peaked at 72 hours. Sv129 mice pretreated with rhIL-11 for 72 hours before femoral artery ligation showed a 3-fold increase in plantar vessel perfusion, leading to faster blood flow recovery; and a 20-fold increase in circulating CD34 ϩ /VEGFR2 ϩ cells after 8 days of rhIL-11 treatment. Histologically, experimental mice had a 3-fold increase in collateral vessel luminal diameter after 21 days of rhIL-11 treatment and a 4.4-fold influx of perivascular CD34 ϩ /VEGFR2 ϩ cells after 8 days of therapy. Functionally, rhIL-11-treated mice showed better hindlimb appearance and use scores when compared with syngeneic mice treated with PBS under the same experimental conditions. Conclusion-These novel findings show that rhIL-11 promotes in vivo mobilization of CD34 ϩ /VEGFR2 ϩ mononuclear cells, enhances collateral vessel growth, and increases recovery of perfusion after femoral artery ligation. Thus, rhIL-11 has a promising role for development as an adjunctive treatment of patients with peripheral vascular disease. 
P eripheral vascular disease (PVD) is a major cause of morbidity and significant health care cost in the United States. 1 It is estimated that Ͼ8 million Americans have PVD, 2 and its prevalence is expected to increase concurrently with the increase of the aging population. The high rate of morbidity associated with this disease has created a need for identification of novel therapies for adjunctive treatment of patients with PVD.
Collateral vessels are preexisting arteriolar connections that may not be used to provide perfusion under normal conditions but can be recruited to bypass the site of acute or chronic vessel occlusion. Collateral vessel growth (arteriogenesis) provides a natural adaptive mechanism to lessen tissue injury caused by PVD. However, this process is insufficient in many patients, and therapies to augment it are needed. Several investigators have shown that intramuscular injection of ex vivo-processed autologous mononuclear cells leads to short-term symptomatic improvement in patients with PVD. 3 Others 4 have reported a correlation between patient outcomes and the number of intramuscularly injected CD34 ϩ cells within the patient's mononuclear cell population. Although these studies have demonstrated favorable safety and feasibility of cell-based therapy for the treatment of patients with PVD, the need for ex vivo processing of mononuclear cells before delivery is a major impediment to the performance of a large-scale study in these patient populations. This creates a need for a novel method of rapid in vivo mobilization of mononuclear cells for the treatment of patients with PVD.
Human blood outgrowth cells (HBOCs) are cultured CD34 ϩ /vascular endothelial growth factor receptor (VEGFR) 2 ϩ mononuclear cells from healthy human subjects. These late-outgrowth cells have a slow initial rate of growth, and they exhibit tremendous proliferative capacity after several weeks in culture, 5 thus serving as useful tools for screening the biological features of vasculoprotective mononuclear cells in in vitro assays. It was recently reported that a 12-mer peptide ligand that binds with high affinity to HBOCs has sequence homology to human interleukin-11 (IL-11). 6 This finding, coupled with reports of high expression of IL-11 receptor ␣ (IL-11R␣) in highly vascular tissues, 7 suggests a potential role for IL-11 as a putative ligand for in vivo mobilization of mononuclear cells and vascular remodeling.
IL-11 is a member of the IL-6 cytokine family. IL-11 is produced by a variety of tissues and has pleiotropic effects on multiple tissues, including promotion of human and murine megakaryocytopoiesis and thrombopoiesis, 8, 9 protection of endothelial cells from alloinjury by upregulation of survivin, 10, 11 and protection against endothelial cell death. 12 Fortuitously, recombinant human IL-11 (rhIL-11) has already been used extensively in patients. 13, 14 Because the clinical efficacy and safety parameters of rhIL-11 have been well characterized in humans, we performed a preclinical study to investigate the role of rhIL-11 as a potential pharmacological agent for in vivo mobilization of CD34 ϩ /VEGFR2 ϩ mononuclear cells and collateral vessel remodeling using a mouse model of hindlimb ischemia. We chose CD34 ϩ /VEGFR2 ϩ cells because these markers are present in humans and mice, have been used to identify mouse progenitor cells that enhance neovascularization during hindlimb ischemia, 15, 16 and will allow for correlation of CD34 ϩ /VEGFR2 ϩ cells in mice and future human studies.
Methods
The supplemental material (available online at http://atvb.ahajournals. org) provides methods not described herein.
Unilateral Hindlimb Ischemia
Unilateral femoral artery ligation was performed using 10-week-old Sv129 mice, as previously described. 17 Briefly, mice were anesthetized with 1.25% isoflurane/O 2 during hindlimb depilation (1 day before surgery) and during hindlimb ischemia surgery. The right femoral artery was exposed through a 2-mm incision and ligated with two 7-0 sutures placed proximal to the origin of the lateral caudal femoral artery. The artery was transected and separated. The wound was irrigated with sterile saline and closed; and cefazolin (50 mg/kg IM), topical furazolidone, and pentazocine (10 mg/kg IM) were administered. The University of North Carolina (Chapel Hill) Institutional Animal Care and Use Committee approved all of our animal procedures.
Laser Doppler Perfusion Imaging
Laser Doppler perfusion imaging was performed as previously described. 17 Briefly, mice were anesthetized with 1.25% isoflurane/O 2 and their body temperature was strictly maintained at 37°C, Ϯ0.5°C, during the entire procedure. Laser Doppler perfusion imaging of plantar foot or adductor thigh of both legs was performed before, immediately after, and at 2, 4, 6, 8, and 14 days after femoral ligation. Images were analyzed using computer software (MoorLDIV5.0). Regions of interest were drawn with respect to anatomic landmarks, and flow rate was calculated. Perfusion in the ligated leg was normalized to the unligated leg. Foot appearance was scored as an index of ischemia: 0, normal; 1 to 5, cyanosis or loss of nail(s) (the score is dependent on the number of nails affected); 6 to 10, partial or complete atrophy of digit(s) (the score reflects number of digits affected); and 11, partial atrophy of the forefoot. Hindlimb use was scored as an index of muscle function: 0, normal; 1, no toe flexion; 2, no plantar flexion; and 3, dragging foot.
All data are reported as meanϮSE. Differences were subjected to unpaired t tests (2-tailed). PϽ0.05 was considered significant.
Results

HBOCs Express IL-11R␣ and Administration of rhIL-11 Activates Downstream STAT-3
We 6 recently identified peptide ligands that bind specifically to HBOCs by screening phage display libraries to identify novel surface markers of vasculoprotective mononuclear cells ( Figure 1A , cartoon). One such 12-mer peptide ligand has sequence homology with human IL-11. This observation, coupled with reports of high expression of IL-11R␣ in highly A, Schematic representation of the screening procedure used to identify peptide ligands that selectively bind to HBOCs. A 12-mer random peptide phage display library was screened using a 2-step selection protocol. First, the library was depleted of ligands binding to common receptors by incubation with a nontarget cell line (human umbilical vein endothelial cells). Second, the unbound phage pool was biopanned on HBOCs. Phages that bound to HBOCs were amplified in Escherichia coli to the original input titer of the library and used for subsequent rounds of biopanning (steps 1-4). After 3 rounds of biopanning, HBOCbound phages were plaque purified for sequence analysis. 6 vascular tissues, 7 prompted us to investigate the potential significance of the IL-11/HBOC interaction on vascular remodeling. As a first step, we confirmed the phenotype of HBOCs by multiparametric investigation consisting of identification of their characteristic cobblestone morphological features, 5 acetylated low-density lipoprotein uptake, 18 and expression of cell surface markers (eg, VEGFR2, CD34, and CD31). These characteristics, along with the lack of expression of CD45 (data not shown), 19 suggest that these HBOCs have properties of dedifferentiated mononuclear cells. 20 To determine whether HBOCs express IL-11R␣, we incubated HBOCs with anti-IL-11R␣ antibody and found that HBOCs robustly express IL-11R␣ on their surface ( Figure 1B ). To determine whether signaling via the IL-11R␣/rhIL-11 (receptor/ligand) axis was intact, we stimulated HBOCs with rhIL-11 and found that rhIL-11-treated cells displayed timedependent phosphorylation of signal transducer and activator of transcription-3 (STAT-3) ( Figure 1C ), a downstream effector molecule that supports cell survival by upregulation of antiapoptotic proteins (eg, survivin) 10 and upregulation of proangiogenic factors (eg, VEGF). 21 These data demonstrate that HBOCs express a functional IL-11R␣ and suggest a link between IL-11/HBOC interaction and IL-11R␣ signaling.
rhIL-11 Stimulates Directed Migration and Tubule Formation in HBOCs
To study the physiological effects of rhIL-11 on HBOCs, we administered rhIL-11 to HBOCs in a Boyden chamber. rhIL-11 administration at 25 ng/mL led to optimal cell migration of HBOCs toward a concentration gradient of rhIL-11 when compared with control ( Figure 2A) . Similarly, treatment of HBOCs with 25-ng/mL rhIL-11 resulted in a 3-fold increase in HBOC proliferation ( Figure 2B ). Because cell migration and cell proliferation are cellular events that support blood vessel assembly, we performed a spheroid assay using HBOCs that were stimulated with rhIL-11 (Figure 2C ) and counted the cumulative sprout length and total number of sprouts for each spheroid. As shown in Figure 2D and 2E, rhIL-11-treated HBOCs showed an 11-fold increase in cumulative sprout length ( Figure 2D ) and an 8-fold increase in sprouts/spheroids ( Figure 2E ) when compared with HBOCs treated with PBS control. These observations indicate that rhIL-11 enhances in vitro migration and proliferation of HBOCs and suggest a potential role of rhIL-11 for in vivo mobilization of CD34 ϩ /VEGFR2 ϩ cells to sites of vascular remodeling. their forward and side scatter. Mice treated with rhIL-11 had significantly more cells in the R 2 quadrant (1.3% of total peripheral blood mononuclear cells), which contained cells expressing both CD34 ϩ and VEGFR2 ϩ surface markers ( Figure 3C , supplemental Figure I , and supplemental Figure  II) , compared with mice treated with PBS ( Figure 3B ). Seventy-two hours after rhIL-11 administration, there was a 20-fold increase in the number of circulating CD34 ϩ / VEGFR2 ϩ cells ( Figure 3D ), compared with PBS-treated mice. By comparison, we observed a 2.8-fold increase in circulating platelets and a 2.5-fold increase in monocytes; we did not observe a significant change in red blood cells, total white blood cells, lymphocytes, or granulocytes (supplemental Figure III) . These data provided the basis for further physiological characterization of rhIL-11.
rhIL-11 Increases Recovery of Perfusion After Femoral Artery Ligation
We used a model of hindlimb ischemia in which the right femoral artery is ligated proximal to the origin of the lateral caudal femoral artery. High-resolution infrared laser Doppler perfusion imaging with a 2-mm sampling depth was then used to measure perfusion in the plantar foot (which is dependent on collateral vessels in the thigh and is a good index of overall leg perfusion 17, [22] [23] [24] ) and in the adductor region. Blood flow decreased to low values in both PBS-and rhIL-11-treated mice immediately after ligation and continued to be decreased in both groups of animals 2 days later ( Figure 4A through 4C) , confirming successful femoral artery ligation in both animal groups. In addition, the lack of significant difference in blood flow between PBS-and rhIL-11-treated animals at these points suggests that rhIL-11 does not have an immediate effect on postocclusive reperfusion. However, when examined at 4, 6, and 8 days after ligation, a greater recovery of plantar perfusion was seen in rhIL-11-treated mice when compared with syngeneic mice treated with PBS ( Figure 4A and 4B and supplemental Figure  IVA) . In addition, rhIL-11-treated mice exhibited a greater increased measure of perfusion in the center of the adductor region, which contains collaterals interconnecting the saphenous and popliteal artery trees with medial trees branching from the femoral and iliac arteries proximal to the lateral circumflex femoral artery ( Figure 4C and 4D and supplemental Figure  IVB) . 17, 22, 24 Together, these observations suggest that rhIL-11 augments preexisting collateral vessel remodeling.
rhIL-11 Improves Functional Recovery and Collateral Vessel Growth
To determine the functional significance of the observed increase in reperfusion previously described, we used a hindlimb use score (index of hindlimb muscle function) and appearance score (index of hindlimb ischemia) 17, 22, 24 and discovered that rhIL-11-treated mice exhibited better hindlimb use and appearance scores than their PBS-treated counterparts (supplemental Figure VA and VB) . To measure preexisting collateral vessel remodeling directly, we performed histomorphometry of the single collateral present in each of the anterior and posterior gracilis muscles at 8 and 21 days after femoral artery ligation. Mice treated with rhIL-11 showed a 1.5-fold increase in collateral vessel luminal diameter on day 8 (data not shown) and a 3-fold increase in collateral vessel luminal diameter on day 21 after femoral artery ligation ( Figure 5A and 5B), compared with PBStreated control mice, indicating that rhIL-11 plays a significant role in time-dependent collateral vessel growth. By comparison, we did not observe a difference in angiogenesis measured by isolectin B4ϩ cell analysis 21 days after femoral artery ligation (supplemental Figure VI) .
rhIL-11 Enhances Influx of CD34
؉
/VEGFR2
؉
Mononuclear Cells Into Perivascular Tissues
Because we observed a 20-fold increase in circulating CD34 ϩ /VEGFR2 ϩ cells associated with rhIL-11 treatment (Figure 3) , we hypothesized that rhIL-11-mediated collateral vessel growth is functionally linked to mobilized CD34 ϩ / VEGFR2 ϩ mononuclear cells. To examine this further, we performed immunohistochemical analysis of the anterior and posterior gracilis muscles to identify CD34 ϩ /VEGFR2 ϩ mononuclear cells in the perivascular tissues 8 days after femoral artery ligation. As shown in Figure 5C ϩ /VEGFR2 ϩ mononuclear cell mobilization peaked 3 days after rhIL-11 treatment, with rhIL-11-treated mice exhibiting a 20-fold increase in circulating CD34 ϩ /VEGFR2 ϩ mononuclear cells compared with PBS control mice on day 3. Each bar represents the meanϮSEM of 6 mice (unpaired Student t test, 2-tailed *PϽ0.05).
clear cells when compared with control mice. By comparison, we only observed a 2.6-fold increase in perivascular CD11b cells after rhIL-11 treatment (supplemental Figure VIIB and  VIIC) . Taken together, these data suggest that rhIL-11 enhances collateral vessel growth by augmentation of the influx of CD34 ϩ /VEGFR2 ϩ and CD11b ϩ mononuclear cells into perivascular tissues.
Discussion
Although native collateral vessels are functional after vessel occlusion, they are often not well developed in short-or long-term vessel occlusion, resulting in significantly de- creased chances of clinical improvement in symptoms. The clinical utility of mononuclear cells for adjunctive treatment of patients with PVD is based on the ability of mononuclear cells to revascularize occluded vessels by growth of preexisting collaterals. Current methods of delivering mononuclear progenitor cells to patients with PVD include intramuscular injection of ex vivo-processed bone marrow-derived or apheresed peripheral blood-derived mononuclear cells into the ischemic limb. 25 These methods of mononuclear cell delivery are cumbersome, invasive, and are also associated with clinically significant procedural complications. Therefore, the identification of a simple and less invasive strategy of revascularization by in vivo mobilization of progenitor cells is crucial to successful treatment of patients with PVD.
Herein, we describe a novel role for rhIL-11 on in vivo mobilization of CD34 ϩ /VEGFR2 ϩ mononuclear cells and augmentation of collateral vessel growth after femoral artery ligation. We observed that rhIL-11 treatment led to a 20-fold increase in circulating CD34 26 or hindlimb 27 ischemia in humans and augmentation of regional blood flow and neovascularization 28 during cerebral or hindlimb ischemia in mice. 29, 30 Our histological analysis of anterior and posterior gracilis muscles shows an increase in the luminal diameter of collateral vessels that was significant (1.5-fold) 8 days after femoral artery ligation and more pronounced (3-fold) 21 days after femoral artery ligation ( Figure 5A and 5B). This finding complements our laser Doppler perfusion imaging data showing faster recovery of plantar and adductor perfusion in rhIL-11-treated mice as early as 4 days after femoral artery ligation ( Figure 4 and supplemental Figure IV) .
The mechanism of rhIL-11-mediated collateral vessel growth is an important topic of future study. Our data suggest that it is likely related to rhIL-11-induced circulating CD34 ϩ / VEGFR2 ϩ mononuclear cells that are recruited to the perivascular ischemic region of the hindlimb, where they may release cytokines/growth factors (paracrine effect), 31 activate STAT-3-dependent pathways (supplemental Figure VIII) , and result in a reduction of apoptosis-mediated cell death (supplemental Figure IX) , as shown by other researchers. 32 Because monocytes and platelets are involved in collateral vessel growth, [33] [34] [35] our data suggest that CD34 ϩ /VEGFR2 ϩ cells are candidate cells that also play a role in collateral vessel growth. We did not characterize the relative contribution of each of the previously described cells to the observed collateral vessel growth, and we cannot exclude the possibility that the observed effects are direct effects of rhIL-11. Because of these limitations, additional studies using chimeric mice with tissue and/or cellular depletion of IL-11 will be necessary for further characterization of this mechanism.
In summary, this report shows that rhIL-11 treatment leads to in vivo mobilization of CD34 ϩ /VEGFR2 ϩ mononuclear cells in mice. Pretreatment of Sv129 mice with rhIL-11 before femoral artery ligation leads to an increase in collateral vessel growth and faster recovery of perfusion, which correlates with functional recovery of hindlimb use. Because rhIL-11 has been used for the treatment of other human diseases, this report suggests the possibility that rhIL-11 could be used as an adjunctive treatment for patients with PVD.
